UPMC at Western Maryland Health System
Welcome,         Profile    Billing    Logout  
 15 Trials 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cox, Charles E
MATIC-2, NCT06070350: Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

Recruiting
3
1000
US
Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA), Component Therapy (CT)
Philip Spinella, Biomedical Advanced Research and Development Authority
Hemorrhagic Shock, Trauma Injury
06/28
10/28
NCT04533464: MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

Recruiting
2
156
US
MultiStem, Placebo
Healios K.K., Memorial Hermann Hospital, United States Department of Defense
Trauma, Adult Stem Cells
12/25
12/25
NCT02525432: Autologous Stem Cell Study for Adult TBI (Phase 2b)

Active, not recruiting
2
37
US
Placebo Infusion, Autologous BMMNC Infusion, Stem Cell Infusion
The University of Texas Health Science Center, Houston, United States Department of Defense, U.S. Army Medical Research and Development Command
Brain Injuries, Traumatic, Brain Injuries, Acute, TBI (Traumatic Brain Injury)
07/24
01/25
NCT05951777: Autologous Adipose Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Recruiting
2
51
US
Autologous HB-adMSCs, Normal Saline
Hope Biosciences, The University of Texas Health Science Center, Houston
Traumatic Brain Injury
12/26
12/26
NCT04063215: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

Completed
1/2
24
US
HB-adMSCs
Hope Biosciences, The University of Texas Health Science Center, Houston
Traumatic Brain Injury
10/24
10/24
NCT06654193: Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

Not yet recruiting
1/2
70
US
Allogeneic HB-adMSCs, Normal Saline
Hope Biosciences, The University of Texas Health Science Center, Houston, University of California, San Francisco, University of Alabama at Birmingham
Acute Kidney Injury
01/28
01/28
COVID-19, NCT06156241: Stem Cell Study for Long Neurological Symptoms

Not yet recruiting
1
12
US
Stem Cell, Allogenic Human Cord Tissue Derived Mesenchymal Stromal Cells (hCTMSCs)
Charles Cox, CBR Systems, Inc.
Post-Acute COVID-19 Syndrome
12/25
02/26
NCT03203941: ACT for CP Individual Patient Expanded Access IND Protocol

No Longer Available
N/A
US
Autologous Cord Blood Stem Cells
Charles Cox
Cerebral Palsy
 
 
PREDICT, NCT03448926: The Registry:

Recruiting
N/A
3000
US
Treatment Recommendation Surveys, 7-gene biosignature
PreludeDx, University of South Florida
DCIS
12/25
12/35
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Mavromatis, Blanche
SOLARIS, NCT04094688: Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer

Active, not recruiting
3
455
US
Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Vitamin D3, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Colorectal Adenocarcinoma
01/26
07/26
Lung-Map Screening Study, NCT03851445: Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Recruiting
2/3
10000
US
Screening Platform
SWOG Cancer Research Network, National Cancer Institute (NCI)
Previously Treated Non-Small Cell Lung Cancer
01/29
01/29
NCT04316117: Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

Active, not recruiting
2
138
Europe, US
Computed Tomography, CAT, CAT scan, computerized axial tomography, Computerized Tomography, CT, CT scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, positron emission tomography scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
08/27
08/27
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Seletyn, Mildred
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Kancharla, Pavan
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC
Active, not recruiting
2
68
US, RoW
Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®
Effector Therapeutics, Medpace, Inc., ICON plc
Non-small Cell Lung Cancer
10/24
12/24
NCT05630183: A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Hourglass Jan 2024 - Jun 2024 : Results from C-800-22 trial for 2L metastatic pancreatic cancer
Recruiting
2
78
US
Botensilimab, AGEN1181, Gemcitabine, Nab-paclitaxel
Agenus Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
12/24
12/24
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37

Download Options